Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
6
|
pubmed:dateCreated |
1992-10-13
|
pubmed:abstractText |
166Holmium ethylenediaminetetramethylene phosphonic acid (166Ho-EDTMP) is a short-lived beta-emitting radionuclide complexed to an aminophosphonate ligand that we have investigated in a canine model as a potential agent for specific marrow ablation before marrow transplantation. After intravenous injections, 166Ho-EDTMP distributed principally to bone and after 24 hours the concentrations of 166Ho-EDTMP in bone were more than 200-fold higher than in any other organ. Increasing dosages of 166Ho-EDTMP led to increasingly prolonged and severe myelosuppression, but myeloablation was not achieved. Histologic examination of recovering animals suggested that the spleen may have acted as a reservoir for circulatory hematopoietic precursors. Four splenectomized animals administered 20 to 30 mCi/kg 166Ho-EDTMP without marrow transplantation died with marrow aplasia, while four splenectomized animals administered similar dosages of 166Ho-EDTMP followed by autologous transplantation recovered. The dose-limiting toxicity of 166Ho-EDTMP appeared to be marrow stromal damage resulting in myelofibrosis, which was reversible. These results suggest that 166Ho-EDTMP can be used to specifically ablate marrow function before marrow transplantation.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Chelating Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Holmium,
http://linkedlifedata.com/resource/pubmed/chemical/Organometallic Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Organophosphorus Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/Radioisotopes
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
0006-4971
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
15
|
pubmed:volume |
80
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
1608-13
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:1520886-Animals,
pubmed-meshheading:1520886-Blood,
pubmed-meshheading:1520886-Bone Marrow,
pubmed-meshheading:1520886-Bone Marrow Transplantation,
pubmed-meshheading:1520886-Bone and Bones,
pubmed-meshheading:1520886-Chelating Agents,
pubmed-meshheading:1520886-Dogs,
pubmed-meshheading:1520886-Hematopoiesis,
pubmed-meshheading:1520886-Holmium,
pubmed-meshheading:1520886-Organometallic Compounds,
pubmed-meshheading:1520886-Organophosphorus Compounds,
pubmed-meshheading:1520886-Radioisotopes,
pubmed-meshheading:1520886-Splenectomy
|
pubmed:year |
1992
|
pubmed:articleTitle |
Specific marrow ablation before marrow transplantation using an aminophosphonic acid conjugate 166Ho-EDTMP.
|
pubmed:affiliation |
Fred Hutchinson Cancer Research Center, Seattle, WA 98104.
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.
|